Contemporary Treatment Options Beyond Chimeric Antigen Receptor (CAR) T-Cell Therapies for Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): A Systematic Literature Review (SLR)

作者
Matthew Alexander Lunning,Christopher Dieyi,Polly Field,Zhen‐Huan Hu,Marta Radwan,Harry H. Miao,Fang Sun,Christine T. Fu,Clare Spooner,Marcelo C. Pasquini
出处
期刊:Biology of Blood and Marrow Transplantation [Elsevier BV]
卷期号:30 (2): S362-S362
标识
DOI:10.1016/j.jtct.2023.12.504
摘要

Refractory or relapsed large B-cell lymphoma (R/R LBCL) remains a significant challenge for patients (Coiffier et al. Blood. 2010). Chimeric antigen receptor (CAR) T-cell therapy has emerged as standard of care for most patients with R/R LBCL after receiving the initial line of treatment (Dreger et al. Blood Adv. 2020). Other therapies with different mechanisms of action also received regulatory approvals as second or third line (2L or 3L) treatment in recent years. We performed an SLR to understand the efficacy and real-world (RW) effectiveness of non–CAR T-cell therapies for R/R LBCL including tafasitamab with lenalidomide (tafa/len), polatuzumab with bendamustine/rituximab (pola-BR), loncastuximab, selinexor, epcoritamab, and glofitamab. We systematically searched MEDLINE, EMBASE, and the Cochrane library for clinical trials or RW studies since 2017 that reported on ≥10 patients who had received the therapies of interest in 2L+ or 3L+. Hand searching of major conference databases was performed to identify additional abstracts. Outcomes of interest were objective response rate (ORR), complete response (CR) rate, progression-free survival, and overall survival (OS). These outcomes and key baseline characteristics were tabulated and summarized. Data from pivotal clinical trials and a recent SLR (Jacobson et al. Tandem Meeting. 2022) on commercially available CAR T-cell therapies were also included to provide context. One pivotal trial for each therapy of interest in 2L+ or 3L+ was identified. At 3L+, ORR ranged from 28% for selinexor to 63% for epcoritamab and glofitamab, and CR ranged from 12% for selinexor to 52% for glofitamab. Median OS ranged from 9.1 months for selinexor to 11.5 months for glofitamab and not reached for epcoritamab (Table). RW studies were also identified for tafa/len (2 for 2L+) and pola-BR (4 for 2L+; 3 for 3L+). Reported outcomes at 2L+ were numerically lower in RW studies (pola-BR, ORR 31%-57%, CR 19%-32%; tafa/len, ORR not reported, CR 9%) versus trials (pola-BR, ORR 63%, CR 53%; tafa/len, ORR 58%, CR 40%) (Table). Statistical analysis of the significance of the differences in baseline characteristics or outcomes between the therapies was not feasible. Currently, the evidence base, particularly RW studies, for non–CAR T-cell R/R LBCL therapies is still limited. In comparison, 78 RW CAR T-cell therapy studies were published (Jacobson et al. Tandem Meeting. 2022) validating the efficacy findings from clinical trials. In general, the reported outcomes of non–CAR T-cell therapies—in clinical trials or RW studies—were numerically lower compared with their CAR T-cell therapy counterparts in both 2L+ and 3L+ except for epcoritamab and glofitamab versus tisagenlecleucel at 3L. Future studies should explore how best to sequence CAR T-cell and non–CAR T-cell therapies in the management of R/R LBCL for preferred outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
transhuman发布了新的文献求助10
刚刚
Sissimummy发布了新的文献求助10
刚刚
Owen的应助被冷暴力采纳,获得10
刚刚
Jane完成签到,获得积分10
1秒前
1秒前
儒雅的裘完成签到,获得积分10
1秒前
顺利大神完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
2秒前
Yee完成签到,获得积分10
2秒前
空空完成签到 ,获得积分10
2秒前
法则尔先生完成签到,获得积分10
2秒前
嗨嗨完成签到,获得积分10
2秒前
杏仁完成签到,获得积分10
2秒前
刘子田完成签到,获得积分10
2秒前
华仔的应助被实验室采纳,获得10
2秒前
123456hhh完成签到,获得积分10
3秒前
礐嶨完成签到,获得积分10
3秒前
完美世界的应助被Ha采纳,获得10
3秒前
Moonlight完成签到 ,获得积分10
3秒前
Orange的应助被xwj采纳,获得10
3秒前
李琛璐完成签到 ,获得积分10
3秒前
ZeKaWa的应助被森林木采纳,获得10
4秒前
发发完成签到,获得积分10
4秒前
4秒前
羊翊婕发布了新的文献求助10
4秒前
yuan发布了新的文献求助10
4秒前
冷静的远山完成签到 ,获得积分10
5秒前
GLUUUUUE完成签到 ,获得积分10
5秒前
離1028发布了新的文献求助10
5秒前
sunziyi完成签到,获得积分20
6秒前
张鹏荣发布了新的文献求助10
6秒前
TSUKI发布了新的文献求助10
6秒前
6秒前
小小完成签到 ,获得积分10
6秒前
呆萌道天完成签到,获得积分10
6秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315